Alternate Health Club Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

Alternate Health Club’s most important evidence distinction is not between its two main medication prices. It is between documentation that a service offers treatment and research showing what a particular treatment achieves. AHC describes online clinical review, compounded injections with vitamin B12 and refrigerated shipping. Those are meaningful service details, but they do not establish that its preparations produce the outcomes reported in trials of branded medicines—or that adding B12 improves those outcomes.

This review examines AHC’s public documentation consulted October 19, 2026, alongside FDA guidance and original clinical research. The company provides more concrete information than a price-only storefront: readers can find formulation descriptions, payment timing, optional consultation charges and shipping terms. However, consultation descriptions, included services and geographic claims are not fully consistent. The useful question is therefore what each document actually supports, which claims remain unverified and what a prospective patient should clarify before submitting payment.

At a glance

Advertised standard prices: Compounded semaglutide with B12 starts at $129 per month; compounded tirzepatide with B12 starts at $169 per month. Both are described as weekly subcutaneous injections in vials designed for 28 days.
Sources: [7] [10]
Microdose programs: AHC lists semaglutide and tirzepatide microdose programs at $99 per month each. The tirzepatide program is described primarily for weight maintenance and stability, not active weight loss.
Sources: [11] [13]
Payment precedes approval: The standard semaglutide flow collects payment with the intake form. A licensed clinician then reviews the request and may approve or decline; payment does not guarantee medication.
Sources: [7]
Compounded status: AHC acknowledges that its compounded medications are not FDA approved. Its pharmacy licensing and accreditation statements are provider claims, not independently verified credentials in this review.
Sources: [6] [1]
Geographic qualification: A cost calculator advertises shipping to all 50 states, but the microdosing page explicitly says that program is not available in all 50 states. The excluded states are not identified in the consulted documentation.
Sources: [8] [11]

Start with the product, not the projected result

AHC’s standard semaglutide offering is compounded semaglutide with vitamin B12, described as a weekly subcutaneous injection starting at $129 per month. Its tirzepatide offering is likewise compounded with B12, described as a dual GLP-1/GIP product and weekly subcutaneous injection starting at $169 per month. Each product page says a vial is designed to cover 28 days. That supply description should not be silently converted into a calendar-month billing interval.

The separate microdose lineup lists semaglutide and tirzepatide at $99 per month each. The semaglutide microdose page confirms a compounded semaglutide-plus-B12 formulation. The tirzepatide microdose page describes its principal purpose as weight maintenance and stability rather than active weight loss. These are distinct advertised programs, not evidence that the standard treatment is available to everyone for $99 or that all three price points buy an interchangeable service.

AHC’s formulation descriptions identify what it markets, but the consulted evidence does not establish outcomes for those particular preparations. Neither a shared ingredient name nor the presence of B12 supplies that missing clinical evidence. Our guide to formulation and route differences explains why product identity matters when interpreting research. Here, it is especially important to keep standard treatment, microdose maintenance and branded-drug trial results separate.

What AHC’s advertised prices establish
Offering or service	Documented price	Important qualification
Compounded semaglutide with B12	From $129 per month	Weekly subcutaneous injection; vial designed for 28 days; clinical approval required
Compounded tirzepatide with B12	From $169 per month	Weekly subcutaneous injection; vial designed for 28 days; clinical approval required
Semaglutide microdose	$99 per month	Compounded with B12; separate microdosing intake required
Tirzepatide microdose	$99 per month	Described primarily for maintenance and stability; separate intake required
Optional direct clinician consultation	$29.99	Semaglutide page offers this before or during treatment

Sources: [7] [10] [11] [13] [5] [3] [4]

Clinical trials do not measure AHC’s performance

AHC’s projection calculator acknowledges that the trials it draws on studied branded medicines, not compounded versions. That distinction deserves more weight than any numerical projection. A calculator can illustrate assumptions drawn from research; it cannot demonstrate how AHC patients actually fare. The consulted documentation does not establish a measured outcome for AHC’s B12 blends or microdose programs, and marketing testimonials do not close that gap.

STEP 1 studied subcutaneous semaglutide over 68 weeks in adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide over 72 weeks in adults with obesity or overweight plus a weight-related complication, also excluding diabetes. Both were randomized trials, but neither tested AHC’s service or preparations. Gastrointestinal tolerability and treatment discontinuations were part of their findings; Novo Nordisk funded STEP 1 and Eli Lilly funded SURMOUNT-1.

These trials support specific conclusions about their studied treatments and populations, not predictions for an individual joining AHC. They also do not establish the effectiveness of microdoses or B12 combinations. Directly comparing percentages across the two studies would not create a randomized head-to-head comparison. Our explanation of why a clinical trial is not a telehealth performance report provides a useful framework for reading provider projections without discarding the underlying research.

Sources: [8] [3] [4]

Compounding disclosures are useful, but not verification

AHC says it does not manufacture medications and that licensed U.S. pharmacies dispense them. Its footer describes the compounding partners as state-licensed and NABP-accredited, while its terms describe affiliated pharmacies as 503A compounding pharmacies. These statements document the company’s representations. The consulted material does not identify the pharmacy that would fill a particular order or independently verify its licensing, accreditation or compliance.

The company explicitly says its compounded medicines are not FDA approved and have not undergone FDA evaluation for safety, efficacy or quality. FDA likewise explains that compounded preparations do not undergo its premarket review. That distinction is important, but nonapproval alone is not proof of clinical inequivalence. AHC also says it prescribes compounds only when a clinician determines commercially available options cannot meet the patient’s needs.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. AHC’s stated policy broadly addresses that issue, but public wording cannot establish how an individual review is conducted. Before paying, ask which pharmacy would dispense the prescription and how the clinician evaluates the need for a compounded preparation. The approved-versus-compounded evidence distinction is about products, not an FDA endorsement of a clinic.

Sources: [6] [12] [1]

Payment starts review, not a guaranteed prescription

The terms identify the business as Alternate Health Club, LLC. AHC says independently contracted, U.S.-licensed clinicians provide clinical services and that completing an assessment does not itself establish a doctor-patient relationship. The site is restricted to users age 18 or older. That website restriction is not a complete medication eligibility policy: the consulted documentation does not provide comprehensive BMI, laboratory, contraindication or other prescribing criteria.

The standard semaglutide page describes a clear sequence: complete the intake form, pay when submitting it and await a licensed clinician’s decision. If approved, instructions arrive by email and medication ships. AHC says payment submits the order for review and nothing more; support contacts the customer if it is declined. No specific medical-review deadline is documented, and the amount retained or returned after a declined request is not clearly established.

The consultation descriptions are less consistent. The semaglutide page says no video call is required in the standard flow and offers a direct clinician consultation for $29.99. The general weight-loss page describes phone or video assessment of current weight, medical history, family background and goals. Other pages promote free consultations or no consultation fees. Those descriptions should not be blended into a promise of unlimited free clinician access; confirm the exact pathway and charge for the intended program.

Sources: [12] [6] [7] [14] [8] [9]

Included care is narrower than an all-inclusive impression

The semaglutide product page lists clinical intake review, a plan based on health history and goals, a prescription only when appropriate and cold-chain express shipping. It also advertises the same monthly rate at every dosage tier, no membership fee and separately priced optional services. These are useful price conditions. They do not clarify every billing question, including the relationship between a monthly advertised charge and a vial described as covering 28 days.

Medication for nausea illustrates why the detailed product page matters. General FAQs describe everything needed as included and mention nausea medication, but the semaglutide page explicitly offers ondansetron ODT separately as optional support. Its price is not documented here. The general FAQs say additional supplements are not required, while the consulted material does not clearly establish whether needles and other administration supplies are included with every order.

AHC’s calculator says HSA or FSA funds may be usable, depending on the plan and confirmation with its administrator. That is not confirmation that AHC accepts insurance or that a particular medicine is covered. The public documentation also does not establish a minimum commitment, prepayment package, recurring-charge consent process or cancellation deadline. A starting price is visible; the complete ongoing financial arrangement still needs clarification before enrollment.

Sources: [7] [9] [8] [12]

Follow-up has a contact route, but no documented cadence

AHC directs clinical questions and treatment-change requests through website live chat or email support. Its semaglutide page says a medical officer reviews every dosage-change request and that this routing ensures a licensed reviewer sees clinical questions. This documents an access pathway, not a response-time guarantee. The optional $29.99 direct consultation is a separate offering; support availability should not be interpreted as continuous, immediate access to a prescriber.

The general weight-loss page says refills depend on the clinician’s assessment and ongoing treatment plan, and that patients may receive follow-up guidance. General FAQs describe automatic monthly medication shipments according to the prescription after visits, with one month shipped at a time. AHC also markets centralized tracking of refills, shipments and progress. Together, these describe an ongoing service, but they do not establish a mandatory follow-up schedule or explain every renewal step.

AHC says treatment length varies and is reviewed as the patient progresses, rather than promising a fixed endpoint. NIDDK similarly describes duration as dependent on response and side effects, with obesity potentially requiring long-term care. For readers evaluating AHC, the missing operational detail is how clinical reassessment happens between payments. Ask who reviews tolerance and response, how concerns are escalated and when another assessment is required—not merely when the next shipment is scheduled.

Sources: [7] [14] [9] [6] [2]

Shipping promises need to be read beside the terms

The semaglutide page advertises typical processing in one to two business days and average delivery in four to 12 business days, within the United States only. These are different stages, not a guaranteed arrival date or a clinical-review timetable. A calculator advertises all-50-state shipping, but the microdose page says that program is not available in every state. Readers need program-specific confirmation rather than relying on the broadest geographic claim.

AHC advertises cold-chain express shipping and notes that ice packs act as thermal buffers and are not expected to arrive frozen. An unfrozen pack does not by itself settle whether medication stayed adequately refrigerated. FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. Our guide to reading cold-chain claims carefully explains why packaging descriptions are not delivery-temperature verification.

The terms authorize AHC or its agents to take possession of dispensed medication and forward it through a commercial carrier. They also assign responsibility for condition, storage, handling and timely delivery to the patient once AHC or its agents possess it, and exclude refunds for several shipping problems. These are contractual statements, not a judgment about enforceability. Ask in advance who handles a temperature complaint, replacement request or package problem.

Sources: [7] [8] [11] [12] [1]

Refund boundaries and program exceptions matter before checkout

AHC’s terms say consultation, medical-review and administrative-processing fees are earned upon submission and are nonrefundable. They further state that all charges become nonrefundable once review is complete or pharmacy fulfillment begins. The product page calls prescription sales final and directs dispensing-error concerns to support. When refunds are issued, it describes a typical three-to-five-business-day period depending on the bank; this is not a guaranteed bank-credit date or a general right to a refund.

Microdosing has a specific exception: all customers, including existing patients, must complete its separate intake form, and orders without it will be canceled and refunded in full. Prior GLP-1 experience is not described as universally required; eligibility remains the clinician’s decision. That explicit missing-form policy should not be extended to other cancellation scenarios. Nor does stopping future service necessarily establish entitlement to repayment for work or dispensing already begun.

The terms also tie advertised medication pricing to affiliated pharmacies and warn that another pharmacy may cost more. A pharmacy-to-AHC information authorization covers prescription, dispensing, fulfillment and identity details for 12 months or until written revocation. The supplied terms also state that the site is not adapted for regulations such as HIPAA and restrict interactions subject to them, while other site materials include HIPAA links and protected-health-information authorizations. Ask AHC to explain how those provisions apply to clinical intake and pharmacy information sharing; this documentation does not establish HIPAA compliance or noncompliance. Readers should request the current complete terms, cancellation instructions and privacy explanation before paying. The consulted terms included an omitted middle section, and the public material does not resolve all privacy or ongoing-billing questions.

Sources: [12] [7] [5]

Questions & answers

Does AHC’s $129 semaglutide price include a clinician conversation?

The semaglutide page includes clinical intake review, but says no video call is required in the standard flow. It separately offers a direct clinician consultation for $29.99 before or during treatment. Other pages describe consultations differently, so confirm whether the interaction you want is included or separately charged.

Sources: [7] [14] [8]

Can an existing AHC patient buy microdoses without another intake?

AHC says no: existing patients also need the dedicated Microdosing Intake Form. Its page promises cancellation and a full refund for orders submitted without that form. Prior GLP-1 use is not a universal prerequisite, but completing the form does not guarantee approval; a licensed clinician determines eligibility.

Sources: [5]

Which pharmacy will fill an AHC prescription?

The consulted documentation does not identify the pharmacy for an individual order. AHC describes licensed U.S. dispensing pharmacies and state-licensed, NABP-accredited compounding partners, but those credentials were not independently verified here. Request the dispensing pharmacy’s identity before payment and clarify how to contact its pharmacist about the prescription.

Sources: [6] [12]

Does AHC serve every state?

Its calculator advertises shipping to all 50 states, while its microdose page expressly says that program is not available in all 50. The excluded states are not documented in the consulted material. Confirm availability for your address and exact program rather than treating nationwide advertising as universal eligibility.

Sources: [8] [11]

Will AHC automatically send another vial?

General FAQs describe automatic monthly shipments according to the prescription after visits, while the weight-loss page makes refills dependent on clinical assessment. The documentation does not clearly establish charge-renewal timing, cancellation steps or a deadline to stop the next shipment. Obtain those details in writing before enrolling.

Sources: [9] [14] [12]

What if an AHC injectable shipment arrives warm?

FDA recommends not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated, and contacting the provider or dispensing pharmacy. AHC says ice packs need not arrive frozen, but that statement does not resolve a warm-medication concern. Its shipping-related refund exclusions make advance clarification of replacement procedures particularly useful.

Sources: [1] [7] [12]

Our assessment

AHC documents a recognizable online compounded-medication service: starting prices, B12 formulations, clinician review, optional direct consultation and refrigerated shipping are all described. Its acknowledgment that compounds are not FDA approved is important. The evidence does not, however, establish outcomes for AHC’s formulations, verify pharmacy credentials or reconcile conflicting consultation and inclusion claims. Before paying, obtain the exact program price and contents, pharmacy identity, state availability, follow-up arrangements, cancellation procedure and declined-order refund treatment. AHC’s documentation offers a starting point for those questions—not proof of clinical equivalence or a dependable prediction of personal results.

Visit Alternate Health Club (AHC)’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Alternate Health Club Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Start with the product, not the projected result

02Clinical trials do not measure AHC’s performance

03Compounding disclosures are useful, but not verification

04Payment starts review, not a guaranteed prescription

05Included care is narrower than an all-inclusive impression

06Follow-up has a contact route, but no documented cadence

07Shipping promises need to be read beside the terms

08Refund boundaries and program exceptions matter before checkout